Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case report

Aoki,Yu; Hamamoto,Yasuo; Ugamura,Aya; Togasaki,Kazuhiro; Suzuki,Takeshi; Kawasaki,Kenta; Hirata,Kenro; Kasuga,Akiyoshi; Sukawa,Yasutaka; Kanai,Takanori; Takaishi,Hiromasa

doi:10.3892/mco.2018.1767

Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case report

Authors:
- Yu Aoki
- Yasuo Hamamoto
- Aya Ugamura
- Kazuhiro Togasaki
- Takeshi Suzuki
- Kenta Kawasaki
- Kenro Hirata
- Akiyoshi Kasuga
- Yasutaka Sukawa
- Takanori Kanai
- Hiromasa Takaishi
View Affiliations

Affiliations: Department of Internal Medicine, Division of Gastroenterology and Hepatology, Keio University School of Medicine, Tokyo 160‑8582, Japan, Keio Cancer Center, Keio University School of Medicine, Tokyo 160‑8582, Japan
Published online on: November 16, 2018 https://doi.org/10.3892/mco.2018.1767
Pages: 113-117

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Scirrhous gastric cancer tends to disseminate to the peritoneum and retroperitoneum, where it induces fibrosis. Retroperitoneal fibrosis (RPF) frequently causes acute renal failure due to ureteral obstruction and it tends to make many of physicians hesitate to initiate systemic chemotherapy. The present study reported the case of a 68-year-old man who was diagnosed with scirrhous gastric cancer with peritoneal and retroperitoneal dissemination, causing acute renal failure due to RPF. Before initiating systemic chemotherapy, the patient became anuric and introduced hemodialysis (HD). Although the patient's performance status was poor, there were no contraindications, such as active infection or severe complications, for systemic chemotherapy. Weekly 5-FU/l LV (5-FU 600 mg/m2, l-LV 250 mg/m2 on days 1, 8, 15, 22, 29 and 36; 8 weeks/cycle) was selected as the feasible treatment for the patient. After chemotherapy the patient opted to withdraw from HD and suffered from no severe toxicity. This indicates, retrospectively, that earlier systemic chemotherapy administration prior to HD introduction may result in improvement of renal function and avoidance of HD.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Tieulent Lortet J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
3	Yashiro M, Chung YS, Nishimura S, Inoue T and Sowa M: Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as ‘soil’ for peritoneal dissemination. Cancer. 77:S1668–S1675. 1996. View Article : Google Scholar
4	Kitamura K, Beppu R, Anai H, Ikejiri K, Yakabe S, Sugimachi K and Saku M: Clinicopathologic study of patients with Borrmann type IV gastric carcinoma. J Surg Oncol. 58:112–117. 1995. View Article : Google Scholar : PubMed/NCBI
5	Dohmen K, Mizukami Y, Tanaka K, Nakamura H, Arase K, Yokogawa Y, Asayama R, Kato A, Kato M, Nakagaki M, et al: Retroperitoneal fibrosis associated with scirrhous gastric cancer. Gastroenterol Jpn. 28:699–705. 1993. View Article : Google Scholar : PubMed/NCBI
6	Peixoto RD, Al Barrak J, Lim H and Renouf D: Gastroesophageal cancer and retroperitoneal fibrosis: Two case reports and review of the literature. World J Gastrointest Oncol. 5:68–70. 2013. View Article : Google Scholar : PubMed/NCBI
7	Sasaki T, Koizumi W, Higuchi K, Ishido K, Ae T, Nakatani K, Katada C, Tanabe S and Saigenji K: Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint. Gan To Kagaku Ryoho. 34:988–992. 2007.(In Japanese). PubMed/NCBI
8	Sawaki A, Yamaguchi K, Nabeya Y, Sakai Y, Osanai H, Denda T, Furue H and Kurihara M: 5 FU/l LV(RPMI) versus S 1 as first line therapy in patients with advanced gastric cancer: A randomized phase III non inferiority trial (ISO 5FU10 study group trial). Eur J Cancer, Suppl. 7:3632009. View Article : Google Scholar
9	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
10	Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009 05 29_QuickReference_8.5×11.pdfSeptember 5–2018
11	Hamamoto Y: Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy. Mol Clin Oncol. 3:539–542. 2015. View Article : Google Scholar : PubMed/NCBI
12	Koep L and Zuidema GD: The clinical significance of retroperitoneal fibrosis. Surgery. 81:250–257. 1977.PubMed/NCBI
13	Vaglio A, Salvarani C and Buzio C: Retroperitoneal fibrosis. Lancet. 367:241–251. 2006. View Article : Google Scholar : PubMed/NCBI
14	Webb AJ and Edwards Dawson P: Malignant retroperitoneal fibrosis. Br J Surg. 54:505–508. 1967. View Article : Google Scholar : PubMed/NCBI
15	Thomas MH and Chisholm GD: Retroperitoneal fibrosis associated with malignant disease. Br J Cancer. 28:453–458. 1973. View Article : Google Scholar : PubMed/NCBI
16	Cronin CG, Lohan DG, Blake MA, Roche C, McCarthy P and Murphy JM: Retroperitoneal fibrosis: A review of clinical features and imaging findings. AJR Am J Roentgenol. 191:423–431. 2008. View Article : Google Scholar : PubMed/NCBI
17	Usher SM, Brendler H and Ciavarra VA: Retroperitoneal fibrosis secondary to metastatic neoplasm. Urology. 9:191–194. 1977. View Article : Google Scholar : PubMed/NCBI
18	Yokoyama R, Tazaki R, Morita H, Nishitani H, Ariumi S, Osuga S, Sohmiya K, Kono T, Narumi Y, Tsuji M, et al: Retroperitoneal fibrosis in a patient with gastric cancer manifested by lower extremity edema and hydrocele. Intern Med. 51:2157–2160. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bisof V, Juretic A, Pasini J, Coric M, Grgic M, Gamulin M, Rakusic Z, Krajina Z, Koretic Basic M, Misir A, et al: Ureteral metastasis as the first and sole manifestation of gastric cancer dissemination. Radiol Oncol. 44:262–264. 2010. View Article : Google Scholar : PubMed/NCBI
20	Shimoyama Y, Ohashi M, Hashiguchi N, Ishihara M, Sakata M, Tamura A, Asato Y, Saitoh K and Mukai M: Gastric cancer recognized by metastasis to the ureter. Gastric Cancer. 3:102–105. 2000. View Article : Google Scholar : PubMed/NCBI
21	Tahara M, Ohtsu A, Boku N, Nagashima F, Muto M, Sano Y, Yoshida M, Mera K, Hironaka S, Tajiri H, et al: Sequential methotrexate and 5 fluorouracil therapy for gastric cancer patients with peritoneal dissemination: A retrospective study. Gastric Cancer. 4:212–218. 2001. View Article : Google Scholar : PubMed/NCBI
22	Dupont JB Jr, Lee JR, Burton GR and Cohn I Jr: Adenocarcinoma of the stomach: Review of 1,497 cases. Cancer. 41:941–947. 1978. View Article : Google Scholar : PubMed/NCBI
23	Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, et al: Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Randomized Phase III study of 5 fluorouracil continuous infusion vs. sequential methotrexate and 5 fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 43:972–980. 2013. View Article : Google Scholar : PubMed/NCBI
24	Nishina T, Boku N, Gotoh M, Shimada Y, Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K, et al: Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Randomized phase II study of second line chemotherapy with the best available 5 fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5 fluorouracil containing regimens (JCOG0407). Gastric Cancer. 19:902–910. 2016. View Article : Google Scholar : PubMed/NCBI
25	Iwasa S, Nakajima TE, Nakamura K, Takashima A, Kato K, Hamaguchi T, Yamada Y and Shimada Y: Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: A retrospective study. Int J Clin Oncol. 16:57–62. 2011. View Article : Google Scholar : PubMed/NCBI
26	Superfin D, Iannucci AA and Davies AM: Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Oncologist. 12:1070–1083. 2007. View Article : Google Scholar : PubMed/NCBI
27	Field KM, Michael M and Part II: Part II: Liver function in oncology: Towards safer chemotherapy use. Lancet Oncol. 9:1181–1190. 2008. View Article : Google Scholar : PubMed/NCBI
28	Janus N, Thariat J, Boulanger H, Deray G and Vacher Launay V: Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 21:1395–1403. 2010. View Article : Google Scholar : PubMed/NCBI
29	Shimada H, Noie T, Ohashi M, Oba K and Takahashi Y: Clinical significance of serum tumor markers for gastric cancer: A systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 17:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
30	Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, Schwaiger M and Fink U: FDG PET imaging of locally advanced gastric carcinomas: Correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 30:288–295. 2003. View Article : Google Scholar : PubMed/NCBI
31	Burgain C, Germain A, Bastien C, Orry X, Choné L, Claudon M and Laurent V: Computed tomography features of gastrointestinal linitis plastica: Spectrum of findings in early and delayed phase imaging. Abdom Radiol (NY). 41:1370–1377. 2016. View Article : Google Scholar : PubMed/NCBI
32	Agnes A, Estrella JS and Badgwell B: The significance of a nineteenth century definition in the era of genomics: Linitis plastica. World J Surg Oncol. 15:1232017. View Article : Google Scholar : PubMed/NCBI
33	Japanese gastric cancer association. Japanese gastric cancer treatment guidelines 2014 (ver.4). Gastric Cancer. 20:1–19. 2017. View Article : Google Scholar
34	NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines^®). version 5.2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5×11.pdfDecember 7–2017